Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Cash from Financing Activities (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Cash from Financing Activities for 11 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 221.02% year-over-year to $1.1 million, compared with a TTM value of $4.6 million through Dec 2025, up 134.15%, and an annual FY2025 reading of $4.6 million, up 134.15% over the prior year.
  • Cash from Financing Activities was $1.1 million for Q4 2025 at Abvc Biopharma, down from $1.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $5.8 million in Q3 2021 and bottomed at -$253500.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $1.2 million, with a median of $702828.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities tumbled 107.11% in 2021, then surged 2639.51% in 2024.
  • Year by year, Cash from Financing Activities stood at $4.3 million in 2021, then tumbled by 105.96% to -$253500.0 in 2022, then soared by 115.16% to $38421.0 in 2023, then soared by 774.06% to $335822.0 in 2024, then surged by 221.02% to $1.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ABVC at $1.1 million in Q4 2025, $1.2 million in Q3 2025, and $1.9 million in Q2 2025.